AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02727738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methimazole
Description: Methimazole starting dose depending on FT3 values (15 mg/day or 20 mg/day or 30 mg/day, for FT3 values \<10 pg/ml, 10-15 pg/ml, >15 pg/ml, respectively) to be tapered by 5 mg/day every 15 days down to values sufficient for FT3 to be normal
Study NCT02727738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methimazole
Description: Methimazole starting dose depending on FT3 values (15 mg/day or 20 mg/day or 30 mg/day, for FT3 values \<10 pg/ml, 10-15 pg/ml, >15 pg/ml, respectively) to be tapered by 5 mg/day every 15 days down to values sufficient for FT3 to be normal
Study NCT01493050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer Carbonate
Description: 1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
Study NCT01493050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium carbonate
Description: 1200 mg of calcium carbonate TID with meals for 26 weeks
Study NCT02896764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cone-beam CT
Study NCT02311374 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Brain connectivity and physiology
Description: Two MRI scanning session will be obtained for each participant both at the same time of day (9AM 12 PM). In one occasion they will be scanned after a night of rested sleep while awake and on another day they will be scanned after one night of sleep deprivation while sleeping in the scanner. In addition to the most sensitive technique selected in the development phase (either DWI or MT), each imaging MRI session will include (1) a resting-state functional connectivity (RSFC; 10 minutes) scan using single-shot T2\*-weighted EPI; and (2) quantitative T1 relaxometry (T1) in a CSF voxel (1mL; cubic) using an inversion recovery experiment with increased interpulse intervals (TI = 200, 300, 400, 500, 700, 1000, 1500, 2000, 3000, 5000, 10000 ms) and a long TR (10000 ms; scan time 2 min) to assess the level of solutes in CSF.
Study NCT03436017 — intervention group
Intervention type: OTHER
Intervention: Metabolomic approach
Description: Biological samples (blood and urine) for a multimodal metabolomic approach
Study NCT04435808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine- oral administration: Duration: up to 90 days or until meeting study termination criteria. Subjects will recieve 600 mg loading dose, followed by 200 mg daily (tablets).~Loading dose: 600 mg once for the first day Maintenance dose: 200 mg, daily
Study NCT02311374 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Brain Wave
Description: ECG will be used to monitor heart rate variability (HRV), which differ significantly between the waking state and the different sleep stages
Study NCT03835754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCS Heart System
Description: The OCS Heart System preserves the heart in a near-physiological, beating state by perfusing the heart with a warmed, donor-blood based perfusate that is supplemented with nutrients and oxygen in a controlled and protected environment
Study NCT04477629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept will be given in the following way - 10mg/kg IV day 1, 5, end of weeks 2, 4, 8, 12 then 5mg/kg every 4 weeks.
Study NCT04477629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Non-experimental: Tacrolimus will be given in the following way - trough level at month 1, 10-12ng/mL; month 2-3, 6-10ng/mL; month 4-6, 4-6ng/mL; months 7-9 taper off.
Study NCT04477629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Non-experimental: MMF is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at 500-1500mg twice a day (BID) (dosed to tolerance and effect).
Study NCT04477629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Non-experimental: CS is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at a dose no less than 5mg/d.
Study NCT00310180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO
Study NCT00310180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Given PO
Study NCT00310180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO
Study NCT00310180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Given PO
Study NCT00310180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00310180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00310180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT00310180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Given PO
Study NCT00310180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00310180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00310180 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy or partial breast irradiation
Study NCT00310180 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy or partial breast irradiation
Study NCT00310180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given PO
Study NCT00310180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen Citrate
Description: Given PO
Study NCT03697304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion
Study NCT03697304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754111
Description: Solution for infusion
Study NCT01699334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational video
Description: The educational video will explain the nature of whiplash injuries and provide a biopsychosocial model for neck pain incorporating both physiological and cognitive-behavioural aspects, reassurance and basic advice on pain relief.
Study NCT01699334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation video
Description: The comparison condition is a relaxation video detailing simple relaxation exercises such as breathing exercises which can be safely used by whiplash patients. The relaxation video contains no explanatory information concerning whiplash injuries or the related symptoms.
Study NCT02622152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right lateral position (2 hours)
Description: Repositioning the patients for two-hours period on the right lateral position
Study NCT02622152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left lateral position (30 minutes)
Description: Repositioning the patients for 30 minutes period on the left lateral position
Study NCT02622152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supine position (30 minutes)
Description: Repositioning the patients for 30 minutes period on the supine position
Study NCT02622152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left lateral position (2 hours)
Description: Repositioning the patients for two-hours period on the left lateral position
Study NCT02622152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supine position (2 hours)
Description: Repositioning the patients for two-hours period on supine position
Study NCT03035565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training with Brain HQ
Description: Computerized Cognitive Training Brain HQ activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
Study NCT03035565 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Crossword Puzzles
Description: Computerized Crossword Puzzles activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
Study NCT03154580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetyl cysteine
Description: Participants will receive 4 capsules at 11:15am on each experimental session day.
Study NCT03154580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: Participants will receive 4 capsules at 11:15am on each experimental session day.
Study NCT01464190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21 (2.5 g tablet containing 500 mg iron)
Description: Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
Study NCT01464190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer carbonate
Description: Film coated, compressed tablets. Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day).
Study NCT01896193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Study NCT01896193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT04358016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Evaluate the effect of Terlipression on the occurance of acute kidney injury in patients with upper-gastroentestinal bleeding
Study NCT04358016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin
Description: Somatostatin
Study NCT01328470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel, cilostazol
Description: Patients with CKD received clopidogrel (75 mg/day)for 14 days Patients with CKD received clopidogrel (150 mg/day)for 14 days Patients with CKD received clopidogrel (75 mg/day)and cilostazol (100 mg twice daily)for 14 days 75mg clopidogrel in patients with normal kidney function for 14 days
Study NCT01793038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (litrezole) plus uFSH arm
Description: literozole tablets 5 mg /day for days 3-7 plus intramuscular injections of uFSH 37.5 IU/day for days 3-12
Study NCT01793038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate-uFSH arm
Description: clomiphene citrate 50 mg tablets twice /day for 5 days plus 37.5 IU uFSH IM injections daily for 10 days
Study NCT03058354 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using intraoperative TIVA with propofol.
Study NCT03058354 — intervention group
Intervention type: PROCEDURE
Intervention: general anaesthesia
Description: Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using general anaesthesia methods other than intraoperative TIVA with propofol.
Study NCT03075267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT010 (BGF MDI) 320/14.4/9.6 µg
Description: A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
Study NCT03075267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT010 (BGF MDI) 160/14.4/9.6 µg
Description: A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
Study NCT03075267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003 (GFF MDI) 14.4/9.6 µg
Description: A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
Study NCT00809445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-site HIV rapid test and brief, prevention counseling
Description: Participants will be offered an on-site oral fluid HIV rapid test with brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach.
Study NCT00809445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On- site HIV rapid test & information
Description: Participants will be offered an on-site oral fluid HIV rapid test with basic info.
Study NCT00809445 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral for off-site HIV testing
Description: Participants will be offered a referral list of HIV testing agencies in the community.
Study NCT03874013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023
Description: MOD-4023 is a long-acting modified recombinant human growth hormone (r-hGH) which utilizes C-terminal peptide (CTP) technology. It will be provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a multi-dose disposable pre-filled PEN.~MOD-4023 will be administered as a SC injection once weekly, using a delivery device.
Study NCT03874013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin
Description: Genotropin® is dispensed in a 2-chamber cartridge. The front compartment contains recombinant somatropin, glycine, mannitol, sodium dihydrogen phosphate anhydrous and disodium phosphate anhydrous. The rear compartment contains m-Cresol and mannitol in water for injections.~A delivery device (Genotropin®) will be used for daily (evening/bedtime) SC administration of Genotropin® into the region of the upper arms, buttocks, thighs or abdomen (8 locations). Injection sites should be rotated.~Dose regimen for Genotropin®: 0.025 mg/kg/day (or 0.175 mg/kg/w divided equally to 7 injections over a week).
Study NCT00818584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV Administration
Study NCT02377856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a, ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
Study NCT02490826 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Table-based T2T intervention
Description: Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on table top materials. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~* Auditory Bombardment;~* Auditory and discrimination;~* Letter-sound knowledge;~* Phoneme identity and phoneme matching;~* Blending;~* Segmentation;~* Rhyme;~* Phoneme manipulation.
Study NCT02490826 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tablet-based T2T intervention
Description: Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on digital materials presented on a tablet. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~* Auditory Bombardment;~* Auditory and discrimination;~* Letter-sound knowledge;~* Phoneme identity and phoneme matching;~* Blending;~* Segmentation;~* Rhyme;~* Phoneme manipulation.
Study NCT01096160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8226 BID, 1 mg
Description: MK-8266 1 mg administered as oral capsules (0.7 mg + 0.3 mg), BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
Study NCT01096160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 BID, 1.8 mg
Description: MK-8266 1.8 mg administered as oral capsules (1 mg + 0.8 mg), BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
Study NCT01096160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 TID, 1.8 mg
Description: MK-8266 1.8 mg administered as oral capsules (0.6 mg), TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
Study NCT01096160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 TID, 2.4 mg
Description: MK-8266 TID (Panel D), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
Study NCT01096160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 TID, 2.4 mg
Description: MK-8266 TID (Panel E), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
Study NCT01096160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo BID (Panel A)
Description: Placebo administered as oral capsules BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
Study NCT01096160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo BID (Panel B)
Description: Placebo administered as oral capsules BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
Study NCT01096160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo TID (Panel C)
Description: Placebo administered as oral capsules TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
Study NCT01096160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo TID (Panel D)
Description: Placebo administered as oral capsules TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
Study NCT03697304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for infusion
Study NCT01096160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo TID (Panel E)
Description: Placebo administered as oral capsules TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
Study NCT04085848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: 4 music therapy sessions during a period of time of 48 hours. Each session lasts 30 minutes.
Study NCT01837251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01837251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD
Study NCT01837251 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT03768778 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Debridement and dural repair
Study NCT02824835 — intervention group
Intervention type: PROCEDURE
Intervention: biopsy during colonoscopy
Description: sampling the lesion with forcept biopter
Study NCT04156126 — intervention group
Intervention type: OTHER
Intervention: Blood Collection
Description: Blood Collection
Study NCT04270617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga program
Description: The intervention will be a 6-week ashtanga yoga program designed by world-renowned yogi Eddie Stern. Eddie Stern is an internationally known Ashtanga yoga teacher, in independent practice not affiliated with NYULH, who has done significant work exploring the physiology and science of yoga. He is not currently engaged in his own research. The yoga protocol for chronic back pain was designed with poses specific to addressing core strength but are gentle enough for patients in pain. The protocol is designed to be directed by a teacher initially but can be done at home and is only 18 minutes in duration.
Study NCT00209001 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture using enhanced Ming Men technique for 20 minutes, twice during 1st week, then once during week 2, 3,and 4.
Study NCT00209001 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture therapy
Description: Sham procedure will be insertion of 5 needles for 20 minutes provided twice during first week, then once per week thereafter.
Study NCT03327818 — intervention group
Intervention type: PROCEDURE
Intervention: hysterectomy
Study NCT03327818 — intervention group
Intervention type: PROCEDURE
Intervention: uterine conservative study
Study NCT02633969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin Capsules low dose
Study NCT02633969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin Capsules high dose
Study NCT05510258 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy
Description: TWO GROUPS CONTROL ND EXPERIMENTAL
Study NCT05510258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: TWO GROUPS CONTROL ND EXPERIMENTAL
Study NCT02364687 — intervention group
Intervention type: RADIATION
Intervention: Computed tomography late enhancement imaging
Study NCT05586997 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bonded-Hyrax
Description: The expansion screw of the bonded-hyrax will be activated until the palatal cusps of the permanent maxillary first molars are opposing the buccal cusps of the permanent mandibular first molars